Bio-Techne Corp (TECH)

Currency in USD
54.00
-0.33(-0.61%)
Closed·
54.06+0.06(+0.11%)
·
TECH Scorecard
Full Analysis
Management has been aggressively buying back shares
TECH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
53.8954.94
52 wk Range
46.0180.95
Key Statistics
Prev. Close
54
Open
54.66
Day's Range
53.89-54.94
52 wk Range
46.01-80.95
Volume
1.87M
Average Volume (3m)
2.28M
1-Year Change
-25.67%
Book Value / Share
12.24
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TECH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
65.31
Upside
+20.94%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Bio-Techne Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Bio-Techne Corp Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Bio-Techne Corp Earnings Call Summary for Q4/2025

  • Bio-Techne beats Q4 2025 EPS forecast with $0.53 vs $0.50 expected; revenue at $317M, slightly above estimates
  • Stock falls 9.09% to $54.64 in pre-market trading despite earnings beat, reflecting broader market concerns
  • Company reports 3% organic revenue growth, launches new products, but faces challenges in biotech funding
  • Expects low single-digit organic growth and 100 basis point margin expansion in FY2026, improving to 200 bps by Q4
  • Divests Exosome Diagnostics business; operating margins decline but future expansion anticipated
Last Updated: 06/08/2025, 15:40
Read Full Transcript

Compare TECH to Peers and Sector

Metrics to compare
TECH
Peers
Sector
Relationship
P/E Ratio
115.3x−1.5x−0.6x
PEG Ratio
−2.050.030.00
Price/Book
4.4x1.1x2.6x
Price / LTM Sales
6.9x2.5x3.3x
Upside (Analyst Target)
20.4%24.0%40.0%
Fair Value Upside
Unlock17.2%4.7%Unlock

Analyst Ratings

12 Buy
4 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 65.31
(+20.94% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.47%
Dividend Yield
0.59%
Industry Median 0.68%
Annualised payout
0.32
Paid quarterly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
0.53 / 0.50
Revenue / Forecast
317.00M / 315.54M
EPS Revisions
Last 90 days

TECH Income Statement

People Also Watch

606.00
GEV
+0.23%
309.60
ELV
-0.13%
196.63
BDX
-1.29%
198.18
LULU
+0.03%
303.35
UNH
+1.17%

FAQ

What Stock Exchange Does Bio-Techne Trade On?

Bio-Techne is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Bio-Techne?

The stock symbol for Bio-Techne is "TECH."

What Is the Bio-Techne Market Cap?

As of today, Bio-Techne market cap is 8.47B.

What Is Bio-Techne's Earnings Per Share (TTM)?

The Bio-Techne EPS (TTM) is 0.47.

When Is the Next Bio-Techne Earnings Date?

Bio-Techne will release its next earnings report on 03 Nov 2025.

From a Technical Analysis Perspective, Is TECH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Bio-Techne Stock Split?

Bio-Techne has split 3 times.

How Many Employees Does Bio-Techne Have?

Bio-Techne has 3100 employees.

What is the current trading status of Bio-Techne (TECH)?

As of 22 Aug 2025, Bio-Techne (TECH) is trading at a price of 54.00, with a previous close of 54.00. The stock has fluctuated within a day range of 53.89 to 54.94, while its 52-week range spans from 46.01 to 80.95.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.